Convection-enhanced delivery has recently entered the clinic and represents a promising new therapeutic option in the field of neurodegenerative diseases and treatment of brain tumors. Understanding of the principles governing delivery and flow of macromolecules within the CNS is still poorly understood and requires more investigation of the microanatomy and fluid dynamics of the brain. Our previously established, reflux-free convection-enhanced delivery (CED) technique and real-time imaging MR method for monitoring CED delivery of liposomes in primate CNS allowed us to closely monitor infusions of putamen. Our findings indicate that CED in putamen is associated with perivascular transport of liposomes, throughout CNS arteries. The results may explain side effects seen in current clinical trials using CED. In addition, they clearly show the necessity for a monitoring technique for future direct delivery of therapeutic agents to the human central nervous system. Based on these findings, we believe that the physiological concept that the perivascular space serves as a conduit for distribution of endogenous molecules within the CNS also applies to interstitially infused agents.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.expneurol.2005.07.009 | DOI Listing |
J Neurooncol
January 2025
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Background: Irinotecan demonstrates anti-tumor efficacy in preclinical glioma models but clinical results are modest due to drug delivery limitations. Convection enhanced delivery (CED) improves drug delivery by increasing intratumoral drug concentration. Real-time magnetic resonance imaging of infusate delivery during CED may optimize tumor coverage.
View Article and Find Full Text PDFWorld Neurosurg
December 2024
Department of paediatric neurosurgery, Children's Hospital named after prof. dr med. Jan Bogdanowicz; Maria Sklodowska-Curie Medical Academy, Warsaw, Poland. Electronic address:
This study explores the integration of chimeric antigen receptor T-cell (CAR-T) therapy with convection enhanced delivery (CED) as a novel approach for treating diffuse intrinsic pontine glioma (DIPG), a highly aggressive pediatric brain tumor with limited treatment options. Preliminary clinical results indicate that CED improves CAR-T cell distribution within the tumor microenvironment, leading to promising anti-tumor responses. However, challenges such as catheter-related complications and potential on-target/off-tumor toxicity remain.
View Article and Find Full Text PDFNucl Med Biol
November 2024
Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada; Department of Medical Imaging, University of Toronto, Toronto, ON, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada. Electronic address:
Introduction: Our objective was to study convection enhanced delivery (CED) of Lu-labeled metal chelating polymer (MCP) conjugated to gold nanoparticles ([Lu]Lu-MCP-AuNP) alone or combined with anti-PD1 immune checkpoint inhibition (ICI) for improving the survival of immunocompetent C57BL/6J mice with orthotopic GL261 murine glioma tumors.
Methods: C57BL/6J mice with GL261 tumors were treated with [Lu]Lu-MCP-AuNP (0.8 or 2.
Neurosurg Clin N Am
January 2025
Department of Neurological Surgery, The Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA.
Convection-enhanced delivery for central nervous system gene therapy is an emerging treatment strategy to modify the course of previously untreatable or inadequately treated neurologic conditions, including brain tumors, metabolic disorders, epilepsy, and neurodegenerative disorders. Ongoing nervous system gene therapy clinical trials highlight advantages and ongoing challenges to this therapeutic paradigm.
View Article and Find Full Text PDFNeuro Oncol
October 2024
Department of Biomedical Engineering and Mechanics, Virginia Tech School of Medicine, Roanoke, VA.
Background: Diffuse midline glioma (DMG) is the most aggressive primary brain tumor in children. All previous studies examining the role of systemic agents have failed to demonstrate a survival benefit; the only standard of care is radiation therapy (RT). Successful implementation of radiosensitization strategies in DMG remains an essential and promising avenue of investigation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!